Methods of treating cancer using IL-21 and monoclonal antibody therapy

There is provided a monoclonal antibody that binds to a Her-2/neu receptor, and an IL-21 polypeptide or fragment of an IL-21 polypeptide as shown in SEQ ID NO:2 from amino acid residue 30 to residue 162, for use in treating cancer in a subject, wherein the subject has 1+ or 2+ overexpression levels...

Full description

Saved in:
Bibliographic Details
Main Authors HOLLY RICHARD D, JOHNSON REBECCA A, KINDSVOGEL WAYNE R, FOSTER DONALD C, HUGHES STEVEN D, CLEGG CHRISTOPHER H, SIVAKUMAR PALLAVUR V, HEIPEL MARK D
Format Patent
LanguageChinese
English
Published 24.04.2013
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:There is provided a monoclonal antibody that binds to a Her-2/neu receptor, and an IL-21 polypeptide or fragment of an IL-21 polypeptide as shown in SEQ ID NO:2 from amino acid residue 30 to residue 162, for use in treating cancer in a subject, wherein the subject has 1+ or 2+ overexpression levels of the Her-2/neu receptor
Bibliography:Application Number: CN201110107971